These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22684241)

  • 21. Design and analytic concepts for periodontal clinical trials.
    Imrey PB; Chilton NW
    J Periodontol; 1992 Dec; 63(12 Suppl):1124-40. PubMed ID: 1479532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management and interpretation of data obtained from clinical trials in pain management.
    Theodore BR; Gatchel RJ
    Pain Pract; 2008; 8(6):461-72. PubMed ID: 19000174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulatory perspectives on data monitoring.
    O'Neill RT
    Stat Med; 2002 Oct; 21(19):2831-42. PubMed ID: 12325099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Data monitoring committees, interim analysis and early termination in paediatric trials.
    Fernandes RM; van der Lee JH; Offringa M
    Acta Paediatr; 2011 Oct; 100(10):1386-92. PubMed ID: 21434998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Quality control in clinical trials].
    Fukushima M
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):172-82. PubMed ID: 8611045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statistical challenges for central monitoring in clinical trials: a review.
    Oba K
    Int J Clin Oncol; 2016 Feb; 21(1):28-37. PubMed ID: 26499195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A computationally simple central monitoring procedure, effectively applied to empirical trial data with known fraud.
    van den Bor RM; Vaessen PWJ; Oosterman BJ; Zuithoff NPA; Grobbee DE; Roes KCB
    J Clin Epidemiol; 2017 Jul; 87():59-69. PubMed ID: 28412468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinician-trialist rounds: 19. Faux pas or fraud? Identifying centers that have fabricated their data in your multi-center trial.
    Pogue J; Sackett DL
    Clin Trials; 2014 Feb; 11(1):128-30. PubMed ID: 24096634
    [No Abstract]   [Full Text] [Related]  

  • 30. Are these data real? Statistical methods for the detection of data fabrication in clinical trials.
    Al-Marzouki S; Evans S; Marshall T; Roberts I
    BMJ; 2005 Jul; 331(7511):267-70. PubMed ID: 16052019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regional differences in multinational clinical trials: anticipating chance variation.
    Marschner IC
    Clin Trials; 2010 Apr; 7(2):147-56. PubMed ID: 20338904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of the core imaging laboratory in multicenter trials.
    Seibyl J; Marek K; Zubal IG
    Semin Nucl Med; 2010 Sep; 40(5):338-46. PubMed ID: 20674593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Quality monitoring in multi-central large sample acupuncture clinical trials].
    Zhao L; Li Y; Zhang FW; Guang H
    Zhongguo Zhen Jiu; 2008 Nov; 28(11):835-7. PubMed ID: 19055291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of missing data in clinical research studies.
    Wisniewski SR; Leon AC; Otto MW; Trivedi MH
    Biol Psychiatry; 2006 Jun; 59(11):997-1000. PubMed ID: 16566901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ethnic sensitive or molecular sensitive beyond all regions being equal in multiregional clinical trials.
    Wang SJ; James Hung HM
    J Biopharm Stat; 2012 Sep; 22(5):879-93. PubMed ID: 22946937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The importance of preservation of the ethical principle of equipoise in the design of clinical trials: relative impact of the methodological quality domains on the treatment effect in randomized controlled trials.
    Djulbegovic B; Cantor A; Clarke M
    Account Res; 2003; 10(4):301-15. PubMed ID: 14989285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The availability of original data and statistics: an improvement in good publication practice.
    Morselli-Labate AM
    JOP; 2003 Nov; 4(6):193-9. PubMed ID: 14614199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statistical analysis and design for estimating accuracy in clinical-center classification of cause-specific clinical events in clinical trials.
    Yan G; Greene T
    Clin Trials; 2011 Oct; 8(5):571-80. PubMed ID: 22013170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent.
    Serebruany VL
    Cardiology; 2011; 120(3):169-71. PubMed ID: 22418766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triggered or routine site monitoring visits for randomised controlled trials: results of TEMPER, a prospective, matched-pair study.
    Stenning SP; Cragg WJ; Joffe N; Diaz-Montana C; Choudhury R; Sydes MR; Meredith S
    Clin Trials; 2018 Dec; 15(6):600-609. PubMed ID: 30132361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.